Clinical Trial

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This trial is a single-arm, single-center, open-label clinical trial to evaluate the safety, efficacy, and metabolism kinetics of CT071 in patients with high-risk newly diagnosed multiple myeloma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-06; most recent amendment 2024-06-11.
Status change: Not Yet Recruiting → Recruiting 2024-06-11
Trial Details
NCT Number NCT06407947
Lead Sponsor Shanghai Changzheng Hospital
Collaborators: CARsgen Therapeutics Co., Ltd.
Conditions Multiple Myeloma
Enrollment 10 participants
Start Date 2024-06-06
Primary Completion 2027-06-03 (estimated)
Study Completion 2027-06-03 (estimated)
Updated on ClinicalTrials.gov 2024-06-12